All In Biotech

NDA 021433 · Glaxo Grp LTD

Flovent Hfa

Fluticasone Propionate · Inhalation

Last checked: Nov 20, 2026Latest source record: Aug 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

May 14, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

738

240 Phase 3, 19 recruiting

FAERS reports

31,126

18,055 serious, 1,768 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2026.

Fluticasone Propionate HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. Limitations of Use Fluticasone Propionate HFA is not indicated for the relief of acute bronchospasm. Fluticasone Propionate HFA is an inhaled corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. () Limitations of use: Not indicated for relief of acute bronchospasm. ()

Mechanism: Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone‑17‑monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • FLOVENT HFA · FLUTICASONE PROPIONATE 0.044MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB
  • FLOVENT HFA · FLUTICASONE PROPIONATE 0.22MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB
  • FLOVENT HFA · FLUTICASONE PROPIONATE 0.11MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.

All 738 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,509
  • drug ineffective2,459
  • headache2,365
  • fatigue2,182
  • off label use1,946
  • pain1,928
  • nausea1,889
  • cough1,819
  • asthma1,697
  • diarrhoea1,677
  • product dose omission issue1,531
  • pneumonia1,488

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004383
2005329
2006341
2007414
2008430
2009383
2010584
2011917
20121,014
2013372
2014485
20151,120
20161,530
20171,239
20181,698
20191,719
20202,076
20211,883
20222,240
20232,740
20243,360
20253,368
20262,500

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Flovent HFA (Fluticasone Propionate)

2024 spending

$9.0M

Beneficiaries

20,884

27,166 claims

Per beneficiary

$433

$25.94 per unit

View as table
YearSpending
2020$463,094,312
2021$464,889,663
2022$445,083,268
2023$394,517,813
2024$9,043,532

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,190 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.